ACAD - ACADIA Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ACAD is currently covered by 22 analysts with an average price target of $29.16. This is a potential upside of $6.9 (31%) from yesterday's end of day stock price of $22.26.

ACADIA Pharmaceuticals's activity chart (see below) currently has 367 price targets and 309 ratings on display. The stock rating distribution of ACAD is 31.71% HOLD and 68.29% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 63.47% with an average time for these price targets to be met of 202.23 days.

Highest price target for ACAD is $28, Lowest price target is $20, average price target is $27.14.

Most recent stock forecast was given by AMI FADIA from NEEDHAM on 08-Apr-2025. First documented stock forecast 06-May-2013.

Currently out of the existing stock ratings of ACAD, 26 are a HOLD (31.71%), 56 are a BUY (68.29%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$28

$10.56 (60.55%)

$28

1 months 9 days ago
(08-Apr-2025)

0/7 (0%)

$13.9 (98.58%)

Hold

$20

$2.56 (14.68%)

$20

2 months 10 days ago
(06-Mar-2025)

16/21 (76.19%)

$2.39 (13.57%)

172

Buy

$27

$9.56 (54.82%)

$27

2 months 20 days ago
(26-Feb-2025)

7/21 (33.33%)

$7.66 (39.61%)

118

Buy

$28

$10.56 (60.55%)

$28

2 months 20 days ago
(26-Feb-2025)

25/37 (67.57%)

$8.66 (44.78%)

486

Hold

$22

$4.56 (26.15%)

$24

3 months 6 days ago
(10-Feb-2025)

16/21 (76.19%)

$3.51 (18.98%)

174

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ACAD (ACADIA Pharmaceuticals) average time for price targets to be met?

On average it took 202.23 days on average for the stock forecasts to be realized with a an average price target met ratio 63.47

Which analyst has the current highest performing score on ACAD (ACADIA Pharmaceuticals) with a proven track record?

CORY KASIMOV

Which analyst has the most public recommendations on ACAD (ACADIA Pharmaceuticals)?

Cory Kasimov works at EVERCORE and has 11 price targets and 7 ratings on ACAD

Which analyst is the currently most bullish on ACAD (ACADIA Pharmaceuticals)?

Alan Carr with highest potential upside - $42.56

Which analyst is the currently most reserved on ACAD (ACADIA Pharmaceuticals)?

Salveen Richter with lowest potential downside - -$5.44

ACADIA Pharmaceuticals in the News

Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised)

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.10 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 10%. A quarter ago, it was expected that...

Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth

Acadia Pharmaceuticals ACAD reported first-quarter 2025 earnings of 11 cents per share, which beat the Zacks Consensus Estimate of 10 cents. In the year-ago quarter, the company had reported earnings of 10 cents per share. Acadia recorded total revenues of $244.3 million, which surpassed the Zacks Consensus Estimate of $241 million. ACAD’s net product revenues...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?